Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
吉利德公司定價4.25萬美元的HIV藥物每年可以製造出只有40美元，遊說者敦促該公司大幅降價。
New research suggests that Gilead Sciences Inc.'s (NASDAQ:GILD) lenacapavir, sold as Sunlenca in the U.S. for HIV prevention, could cost patients just $40 annually.
新的研究表明，吉利德科學公司（納斯達克：GILD）的Lenacapavir（在美國銷售的Sunlenca，用於HIV預防）可能會讓患者每年只需支付40美元。
Currently priced at $42,250 for the first year, campaigners urge the company to significantly reduce costs globally.
目前的價格爲首年42250美元，倡導者敦促該公司全球大幅降低成本。
In December 2022, the FDA approved Lenacapavir in combination with other antiretrovirals to treat HIV-1 infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection.
2022年12月，FDA批准Lenacapavir與其他抗逆轉錄病毒藥物聯合治療重度耐多藥HIV-1感染的成年人。
At the International AIDS Conference in Munich, experts presented a study estimating that a generic version of lenacapavir could be produced for $40 a year, assuming 10 million people used it annually.
在慕尼黑國際艾滋病會議上，專家發表了一項研究，估計一種Lenacapavir的仿製藥每年可以以40美元的價格生產，假設每年1000萬人使用它。
The Guardian...
《衛...
登入免費觀看全文
登入/註冊